Thank you for the Registration! Please check your mailbox. Simply click on the button in your email and you are successfully logged in.
With your Log-In you can save your favorite events to you calendar and give RSVP to certain events.
No email in your mailbox? Please check your spam folder or try again.
It seems you haven't registered yet!
Register now and become part of the event and the global Falling Walls Community. We will send you news about this and future events and keep you updated about the most exciting breakthroughs in science.
You can withdraw your consent at any time free of charge and without giving reasons.
Enter your email for free registration or login
Simply enter your email address to sign up for free for the event or log in to your account. You will directly receive an email allowing you to log in without a password.
Login failed
You want to login with an account which needs advanced authentification via password. Please use the regular login interface for this email address or register with a different email address for participating in the summit passwordless.
T-knife has developed a special mouse strain that generates efficient anti-cancer molecules. Using these molecules the immune system of a cancer patient can be reprogrammed to attack tumor cells and eliminate them just like they would attack a virus-infected cell. T-knife’s technology has the potential to revolutionise the treatment of solid tumors just as CAR-T have for leukemia. T cell therapy has been shown to lead to complete remission of tumors in patients refractory to virtually any other available therapy. This gives hope to be able to treat patients which have no options left.
ELISA KIEBACK, T-KNIFE
Jeanette Libera-Körner, MAX DELBRÜCK CENTER
T-knife’s humanized TCR (T cell receptor) mice carry the entire human TCR gene loci (about 2 MB of DNA) and recombine a broad repertoire of fully human TCRs – similarly to Ig-locus transgenic mice that produce fully human antibodies. This technology allows highly efficient “factory-like” generation and selection of TCRs for virtually any human tumor antigen. Since the mouse immune system is not tolerant to most human tumor antigens, T-knife’s TCRs are of optimal affinity. For tumor therapy, the TCRs are transferred ex vivo to autologous patient T cells. These TCR-modified T cells can then efficiently eliminate tumors.
For TCR-modified T-cells to mediate an efficient anti-tumor response, the source of the TCR is of decisive importance. The TCRs currently under clinical development are derived either from humans, conventional mice or are modified in vitro. This negatively impacts the affinity and specificity of the receptor leading to a poor risk/benefit profile when used in patients. In contrast, T-knife’s TCRs recognise the target similar to how they would recognise a virus in an efficient natural immune response. A phase I clinical study is planned for 2018.
We use cookies and other technologies to collect data about your use of our site and about your browser, device and location. We process this data to help us understand how the site is used and to personalize our content and the advertising you see on this and other sites we also share this data with advertising, social media and analytics partners for the same purposes. By choosing “Accept All” you agree that we store cookies on your device and process the data for the aforementioned purposes . You may revoke your consent at any time by choosing the respective settings. For more information on the processing of personal data and what specific services we use see our Privacy Policy
Privacy Preference Center
We use cookies and other technologies to collect data about your use of our site and about your browser, device and location. We process this data to help us understand how the site is used and to personalize our content and the advertising you see on this and other sites we also share this data with advertising, social media and analytics partners for the same purposes. By choosing “Accept All” you agree that we store cookies on your device and process the data for the aforementioned purposes . You may revoke your consent at any time by choosing the respective settings. For more information on the processing of personal data and what specific services we use see our Privacy Policy
Necessary Cookies
These cookies are required to provide you with our site and its functions. Since storing these cookies is necessary for the provision of our site and its functions, you cannot disable them. If you block these cookies via you browser settings our site may not function properly.
Analyse Cookies
These cookies enable us to use website analytics in order to improve our site or provide you with personalized content. They may be set by us or by third party providers whose services we have added to our pages.
Marketing Cookies
These cookies enable us to use online marketing and advertising in order to provide you on this or on other sites with personalized advertisement. They may be set by us or by third party providers whose services we have added to our pages.